-
Basel, November 8, 2021 — Novartis today announced results from a pooled post-hoc analysis of Phase III ORION-9, -10 and -11 trials, exploring the impact of body mass index (BMI) levels on the efficacy and safety of twice-yearly** Leqvio® (inclisiran). At month 17, Leqvio was well-tolerated and provided effective and sustained reduction of…Reimagine MedicineMedical Innovations
-
Basel, November 04, 2021 — Novartis today announced that a Phase II study of investigational iptacopan (LNP023) – a first-in-class, oral, selective factor B inhibitor – in patients with C3 glomerulopathy (C3G) met primary endpoints in both patient cohorts1. The data were presented at the American Society of Nephrology (ASN) 2021 Annual Meeting.Reimagine MedicineMedical Innovations
-
Basel, November 4, 2021 — Novartis will highlight new data on Scemblix® (asciminib), recently approved by the US Food and Drug Administration, as well as its next-generation CAR-T platform and the latest research results for an array of hematology medicines at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition (…Reimagine MedicineOncologyMedical Innovations
-
Basel, October 27, 2021 — Novartis today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA) and Type II Variation, respectively, for Kymriah® (tisagenlecleucel) in adult patients with relapsed or refractory (r/r) follicular…Reimagine MedicineMedical Innovations
-
Ad-hoc-Mitteilung gemäss Art. 53 KRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Annonce événementielle selon l’art. 53 RCReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsInnovationAd Hoc
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineOncologyMedical InnovationsCancerAd Hoc
-
Basel, June 23, 2021 — VISION data published today in The New England Journal of Medicine (NEJM) shows that 177Lu-PSMA-617 plus standard of care (SOC) significantly improved both overall survival (HR = 0.62 [95% CI: 0.52−0.74]; P<0.001; median 15.3 vs 11.3 months) and imaging-based progression-free survival (HR = 0.40 [99.2% CI: 0.29−0.57…Reimagine MedicineOncologyMedical Innovations
-
Basel, July 14, 2021 — Novartis today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase III REACH3 trial demonstrating Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-refractory/dependent chronic graft-versus-host disease (GvHD) compared to best available therapy (BAT…Reimagine MedicineMedical Innovations
-
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineMedical InnovationsAd Hoc
-
Basel, August 17, 2021 – Novartis today announced that the China National Medical Products Administration (NMPA) has further approved Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in pediatric patients (six years and older with a body weight ≥50 kg) who are candidates for systemic therapy or phototherapy, making…Reimagine MedicineMedical Innovations